Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy-Reference-Cited by-同舟云学术

Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy

Published:2022-06 Issue:6 Volume:28 Page:305.e1-305.e9
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Hoogland Aasha I.^ORCID,Barata Anna,Logue Jennifer,Kommalapati Anuhya,Hyland Kelly A.,Nelson Ashley M.^ORCID,Eisel Sarah L.,Small Brent J.^ORCID,James Brian W.,Christy Shannon M.^ORCID,Bulls Hailey W.,Booth-Jones Margaret,Jayani Reena V.^ORCID,Jain Michael D.,Mokhtari Sepideh,Chavez Julio C.,Lazaryan Aleksandr,Shah Bijal D.,Locke Frederick L.,Jim Heather S.L.^ORCID

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference53 articles.

1. Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial;Locke;Lancet Oncol,2019

3. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

4. Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL;Abramson;J Clin Oncol,2018

5. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet,2020

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma;Frontiers in Oncology;2024-06-11

2. Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb;Pharmaceuticals;2024-05-06

3. Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?;HemaSphere;2024-05

4. Cancer related cognitive impairment: a downside of cancer treatment;Frontiers in Oncology;2024-04-23

5. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?;Clinical Hematology International;2024-03-13